-
FDA approves GLP-1 generic
On Dec. 23, the FDA approved Hikma Pharmaceuticals' liraglutide injection, a generic version of Novo Nordisk's Victoza. -
FDA reaffirms end of Mounjaro shortage
In early October, the FDA announced that the two-year shortages of Mounjaro and Zepbound were resolved. After pushback from compounding pharmacies, the agency reaffirmed the decision on Dec. 19. -
The proliferation of counterfeit weight loss drugs: 5 notes
As weight loss medications such as Ozempic, Wegovy and Mounjaro soar in popularity, counterfeit and otherwise unapproved versions of these drugs are making their way into the market, putting patients at risk. -
Weight loss drugs ranked by recent price changes
The prices for some GLP-1s have dropped significantly in recent years for individuals covered by Medicare and commercial insurance, according to a November report from HHS. -
Another study links Ozempic to rare vision loss
A preprint study confirmed an association between Ozempic's active ingredient and an increased — but overall low — risk of vision loss. -
GLP-1 barriers begin to break down
Barriers to accessing GLP-1 medications are beginning to break down as drug manufacturers, insurers, and lawmakers look to expand availability, lower costs, and address continued high demand. -
Eli Lilly, telehealth firm team up to expand Zepbound access
Eli Lilly has partnered with the telehealth company Ro to expand access to single-dose vials of its popular weight loss drug Zepbound. -
Weight loss drug fill rates, by state
Alaska recorded the highest percentage of medication fills for weight loss drugs this year, according to data from GoodRx. -
Zepbound fills increase 300% this year: GoodRx
Medication fills for weight loss drugs such as Zepbound and Wegovy rose sharply this year, despite high out-of-pocket costs for patients, according to a Dec. 5 analysis from GoodRx. -
GLP-1's $411B conundrum
Should employers, patients, or insurers bear the largest share of an annual $411 billion cost? -
Experimental obesity drug leads to 20% weight loss in 1 year
Amgen's experimental GLP-1 drug, MariTide, resulted in an average 20% reduction in body weight in a 52-week phase 2 study, the company said Nov. 26. -
Biden administration proposes Medicare coverage for weight loss drugs: 10 things to know
The White House is pitching broader coverage of weight loss drugs for millions of Americans on Medicare and Medicaid. -
Drugmakers, pharmacists battle over who gets obesity drugs: 5 things to know
The battle over who should provide obesity and diabetes drugs like Ozempic and Wegovy has reached a critical point, as manufacturers and compounding pharmacies clash over the demand of these medications, NPR reported Nov. 20. -
53% of US adults are eligible for Ozempic, Wegovy: Study
Researchers estimate that 136.8 million adults in the U.S. are eligible for semaglutide, the generic for Novo Nordisk's Ozempic, Wegovy and Rybelsus. -
Ozempic, Wegovy may help treat alcohol addiction: 3 study findings
A recent study conducted in Sweden found that GLP-1 agonists such as Ozempic and Wegovy may help reduce alcohol consumption and related harms in individuals diagnosed with alcohol use disorder. -
Bariatric operations & GLP-1s: What to know
The ever-rising popularity of GLP-1 medications is reshaping the landscape of bariatric surgeries — but experts say patients could be overlooking key factors when choosing between the two weight loss treatments. -
Employer interest in Ozempic copycats grows
Telehealth companies selling low-cost, compounded versions of popular weight-loss drugs, including Ozempic and Wegovy, are drawing increased interest from employers, Bloomberg reported Oct. 29. -
Bariatric surgeries plunge in GLP-1 era: New study
Between 2022 and 2023, prescriptions for GLP-1 drugs soared 132.6% while bariatric surgery rates fell 25.6%, according to a new study from researchers at Boston-based Harvard Medical School and Brigham and Women's Hospital. -
3 recent Ozempic studies to know
Researchers have recently identified more potential uses for Ozempic and other GLP-1 medications, including treating opioid use disorder, alcohol use disorder and Alzheimer's disease. -
Novo Nordisk's GLP-1 pill reduces cardiovascular events by 14%
Novo Nordisk's GLP-1 medication, Rybelsus, reduced major adverse cardiovascular events by 14% compared to a placebo in a phase 3 trial, the drugmaker said Oct. 21.
Page 1 of 50